Selective Inhibition of Mutant Ras Protein through Covalent Binding
The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
One of the first oncogenes to be discovered and one of the most prevalently mutated tumor genes is Ras. Shokat et al. and Gray et al. have succeeded in discovering allosteric inhibitors and inhibitory nucleotide analogues, respectively, of K-Ras proteins that covalently and selectively bind G12C-mutant K-Ras. These strategies of specifically targeting a mutant form of Ras may offer an opportunity for cancer-selective therapies that spare normal tissue.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This can be a significant advantage in cancer treatment, because point mutations of target proteins often generate resistance to drug treatment [42, 43].”
From The design and development of covalent protein-protein interaction inhibitors for cancer treatment (2020) · cites this paper as [42]
Citations
Cites
K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions
Ostrem, J. M., Peters, U., Sos, M. L., Wells, J. A., & Shokat, K. M. (2013) · Nature · doi:10.1038/nature12796 · Cited by 2,557
Therapeutic Strategies for Targeting Ras Proteins
Gysin, S., Salt, M., Young, A., & McCormick, F. (2011) · Genes & Cancer · doi:10.1177/1947601911412376 · Cited by 323
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie International Edition · doi:10.1002/anie.201307387 · Cited by 300
Shima, F., Yoshikawa, Y., Ye, M., Araki, M., Matsumoto, S., Liao, J., Hu, L., Sugimoto, T., Ijiri, Y., Takeda, A., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1217730110 · Cited by 293
PI3K and MEK inhibitor combinations: examining the evidence in selected tumor types
Britten, C. D. (2013) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-013-2121-1 · Cited by 216
Ras inhibition via direct Ras binding—is there a path forward?
Wang, W., Fang, G., & Rudolph, J. (2012) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2012.07.082 · Cited by 104
Self-citationKalbitzer, H. R., Rosnizeck, I. C., Munte, C. E., Narayanan, S. P., Kropf, V., & Spoerner, M. (2013) · Angewandte Chemie International Edition · doi:10.1002/anie.201305741 · Cited by 68
Covalent modification as a strategy to block protein–protein interactions with small-molecule drugs
Way, J. (2000) · Current Opinion in Chemical Biology · doi:10.1016/s1367-5931(99)00049-6 · Cited by 55
Therapeutic Targeting of Oncogenic K‐Ras by a Covalent Catalytic Site Inhibitor
Lim, S. M., Westover, K. D., Ficarro, S. B., Harrison, R. A., Choi, H. G., Pacold, M. E., Carrasco, M., Hunter, J., Kim, N. D., Xie, T., et al. (2014) · Angewandte Chemie · doi:10.1002/ange.201307387 · Cited by 31
Kalbitzer, H. R., Rosnizeck, I. C., Munte, C. E., Narayanan, S. P., Kropf, V., & Spoerner, M. (2013) · Angewandte Chemie · doi:10.1002/ange.201305741 · Cited by 12
Cited by
Targeted Covalent Inhibitors for Drug Design
Baillie, T. A. (2016) · Angewandte Chemie International Edition · doi:10.1002/anie.201601091 · Cited by 578
Targeted Degradation of Oncogenic KRAS G12C by VHL-Recruiting PROTACs
Bond, M. J., Chu, L., Nalawansha, D. A., Li, K., & Crews, C. M. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00411 · Cited by 450
Covalent Inhibition in Drug Discovery
Ghosh, A. K., Samanta, I., Mondal, A., & Liu, W. R. (2019) · ChemMedChem · doi:10.1002/cmdc.201900107 · Cited by 265
The Cysteinome of Protein Kinases as a Target in Drug Development
Chaikuad, A., Koch, P., Laufer, S. A., & Knapp, S. (2018) · Angewandte Chemie International Edition · doi:10.1002/anie.201707875 · Cited by 225
Bond, M. J., & Crews, C. M. (2021) · RSC Chemical Biology · doi:10.1039/d1cb00011j · Cited by 221
Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain
Akçay, G., Belmonte, M. A., Aquila, B., Chuaqui, C., Hird, A. W., Lamb, M. L., Rawlins, P. B., Su, N., Tentarelli, S., Grimster, N. P., et al. (2016) · Nature Chemical Biology · doi:10.1038/nchembio.2174 · Cited by 207
Drugging Ras GTPase: a comprehensive mechanistic and signaling structural view
Lu, S., Jang, H., Gu, S., Zhang, J., & Nussinov, R. (2016) · Chemical Society Reviews · doi:10.1039/c5cs00911a · Cited by 188
The Hallmarks of Cancer from a Redox Perspective
Hornsveld, M., & Dansen, T. B. (2016) · Antioxidants and Redox Signaling · doi:10.1089/ars.2015.6580 · Cited by 115
“Another way would be by targeting acquired, redox-sensitive cysteines that are unique to cancer cells due to mutation, as was explored, for instance, for the oncogenic RasG12C mutation (194).”
The design and development of covalent protein-protein interaction inhibitors for cancer treatment
Cheng, S.-S., Yang, G.-J., Wang, W., Leung, C.-H., & Ma, D.-L. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00850-0 · Cited by 98
“This can be a significant advantage in cancer treatment, because point mutations of target proteins often generate resistance to drug treatment [42, 43].”
BackgroundCovalent targeting of acquired cysteines in cancer
Visscher, M., Arkin, M. R., & Dansen, T. B. (2016) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.11.004 · Cited by 95
“They found that these compounds bound in a ‘cryptic binding site’ in the so-called switch II region that is in the vicinity of G12C but is distinct from the GTP binding pocket (for a review see [33]).”
Discovery of High-Affinity Noncovalent Allosteric KRAS Inhibitors That Disrupt Effector Binding
McCarthy, M. J., Pagba, C. V., Prakash, P., Naji, A. K., van der Hoeven, D., Liang, H., Gupta, A. K., Zhou, Y., Cho, K.-J., Hancock, J. F., et al. (2019) · ACS Omega · doi:10.1021/acsomega.8b03308 · Cited by 90
Quantum Chemical-Based Protocol for the Rational Design of Covalent Inhibitors
Schirmeister, T., Kesselring, J., Jung, S., Schneider, T. H., Weickert, A., Becker, J., Lee, W., Bamberger, D., Wich, P. R., Distler, U., et al. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b03052 · Cited by 97
Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents
Wan, Y., Dai, N., Tang, Z., & Fang, H. (2018) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2018.01.076 · Cited by 90
Shin, S. H., Kim, H. J., Hwang, D. W., Lee, J. H., Song, K. B., Jun, E., Shim, I. K., Hong, S.-M., Kim, H. J., Park, K.-M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14901 · Cited by 57
Tong, Y., Zhang, P., Yang, X., Liu, X., Zhang, J., Grudniewska, M., Jung, I., Abegg, D., Liu, J., Childs‐Disney, J. L., et al. (2024) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2306682120 · Cited by 53
Zielgerichtete kovalente Inhibitoren für das Wirkstoffdesign
Baillie, T. A. (2016) · Angewandte Chemie · doi:10.1002/ange.201601091 · Cited by 44
Gupta, A. K., Wang, X., Pagba, C. V., Prakash, P., Sarkar‐Banerjee, S., Putkey, J. A., & Gorfe, A. A. (2019) · Chemical Biology & Drug Design · doi:10.1111/cbdd.13519 · Cited by 44
Approaches to inhibiting oncogenic K-Ras
Gorfe, A. A., & Cho, K. (2019) · Small GTPases · doi:10.1080/21541248.2019.1655883 · Cited by 38
“K-Ras may have a better chance of eventual success [78],”
BackgroundComputational allosteric ligand binding site identification on Ras proteins
McCarthy, M. J., Prakash, P., & Gorfe, A. A. (2016) · Acta Biochimica et Biophysica Sinica · doi:10.1093/abbs/gmv100 · Cited by 31
“There are three major Ras proteins in humans: N, H, and K-Ras.”
BackgroundInfluentialMilroy, L.-G., & Ottmann, C. (2014) · ACS Chemical Biology · doi:10.1021/cb500555h · Cited by 19
Correlation of O2 transport on the micro and macro scale.
Honig, C. R., & Gayeski, T. E. (1982) · PubMed · Cited by 18
KRASG12C inhibitor: combing for combination
Chakraborty, A. (2020) · Biochemical Society Transactions · doi:10.1042/bst20200473 · Cited by 15
How to make an undruggable enzyme druggable: lessons from ras proteins
Sayyed–Ahmad, A., & Gorfe, A. A. (2020) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2020.05.003 · Cited by 12
Covalent drug – An emerging framework for targeted drug development
Bhole, R. P., Joshi, G. O., Kapare, H. S., Chikhale, R. V., & Chaudhari, S. Y. (2024) · Results in Chemistry · doi:10.1016/j.rechem.2024.101615 · Cited by 13
Das Cysteinom der Proteinkinasen als Zielstruktur in der Arzneistoffentwicklung
Chaikuad, A., Koch, P., Laufer, S., & Knapp, S. (2017) · Angewandte Chemie · doi:10.1002/ange.201707875 · Cited by 10
The ubiquitin code of RAS proteins: Decoding its role in cancer progression
Shi, Y., Shen, Y., Zhang, X., Zhu, N. W., Ding, Y., Yuan, Y., & Wang, J. (2025) · iScience · doi:10.1016/j.isci.2025.113029 · Cited by 8
“86,221 However, malignant cells may disrupt this equilibrium through multifaceted dysregulation.”
Franz, M., Mörchen, B., Degenhart, C., Gülden, D., Shkura, O., Wolters, D. A., Koch, U., Klebl, B., Stoll, R., Helfrich, I., et al. (2021) · ChemMedChem · doi:10.1002/cmdc.202100167 · Cited by 4
Pagba, C. V., Gupta, A. K., Dilsha, K. M., Sadrpour, P., Jakubec, J. L., Prakash, P., van der Hoeven, D., Cho, K., Gilbertson, S. R., & Gorfe, A. A. (2024) · ChemBioChem · doi:10.1002/cbic.202300827 · Cited by 1
Pagba, C. V., Dilsha, K. M., Ojha, R., Jakubec, J. L., Liang, X., Sianoya, A. C., Medina, P. M. B., Gilbertson, S. R., & Gorfe, A. A. (2026) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.6c00129
BindingDB (2016) · UC San Diego · doi:10.7270/q2fn1513
BindingDB Entry 50001688: Small-molecule Mcl-1 inhibitors: Emerging anti-tumor agents.
BindingDB (2020) · UC San Diego · doi:10.7270/q2zg6vs2
Metadata
- Authors
- Rudolph, J., & Stokoe, D.
- Affiliations
- Genentech (US)
- Corresponding author
- Rudolph, Joachim
- Venue
- Angewandte Chemie International Edition
- Publisher
- Wiley
- Published
- 2014-03-03
- Volume
- 53
- Issue
- 15
- Pages
- 3777-3779
- ISSN
- 1433-7851 (ISSN-L)
- 1521-3773
- OpenAlex
- W2122727567
- Cited by
- 29
- References
- 10
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 3 · 2021: 2 · 2020: 4 · 2019: 4 · 2018: 1 · 2017: 3 · 2016: 6 · 2015: 2 · 2014: 1
- FWCI
- 1.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Angewandte Chemie International Edition (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Tyrosine Phosphatases
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Melanoma and MAPK Pathways
- Keywords
- KRAS, covalent inhibitors, allosteric inhibitors, oncogene inhibition, targeted cancer therapy
- MeSH terms
- Binding Sites, Humans, Signal Transduction, ras Proteins, Mutant Proteins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.